BioCentury | Aug 26, 2020
Deals

Aug. 25 Quick Takes: A slew of private financings led by Connect’s $115M series C; plus BMS-Forbius, Takeda deals, Bio-Thera-BeiGene and adds to HKSE, NASDAQ queues

...to start Phase III trials of CBP-201, an anti-IL-4R mAb to treat atopic dermatitis, and CBP-307...
BioCentury | Jan 4, 2019
Financial News

Suzhou Connect raises $55M series B, plans Phase Ib of dermatitis candidate

...product, CBP-307, is in two Phase II trials to treat ulcerative colitis and Crohn's disease. CBP-307...
...see "Connect Raises $20M Series A Round" ). Suzhou Connect Biopharmaceuticals Ltd., Taicang, China Elizabeth S. Eaton CBP-201 CBP-307 Suzhou...
BioCentury | Jan 3, 2019
Financial News

Suzhou Connect raises $55M series B, plans Phase Ib of dermatitis candidate

...product, CBP-307, is in two Phase II trials to treat ulcerative colitis and Crohn's disease. CBP-307...
...IL-4R (IL-4RA; CD124) - IL-4 receptor; S1PR1 (S1P1; EDG1) - Sphingosine 1-phosphate receptor 1 Elizabeth S. Eaton CBP-201 CBP-307 Suzhou...
BioCentury | Jan 26, 2017
Financial News

Connect raises $20M series A round

...and Cowin Venture Capital. The company is planning a Phase II study of lead candidate CBP-307...
...of a second candidate, CBP-201, which is in development to treat atopic dermatitis and asthma. CBP-307...
Items per page:
1 - 4 of 4